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used, reserving TA access for patients with severe morphological or pathological impediments to navigating the iliofemoral arteries. In a PARTNER-I as-treated analysis of these randomized patients (PARTNER A), early mortality and risk of stroke were higher after TA-TAVR than TF-TAVR. 5 Whether these results reflect risk after a surgical (TA) versus TF procedure or patient selection factors (TA merely being a marker for cardiovascular risk factors) is unknown.
During the continuing access phases of the trial, the allocation strategy for TF versus TA access was at the discretion of the heart team at each institution, and use of TA access steadily increased to 50% ( Figure IA and IB in the online-only Data Supplement). Today, smaller sheath delivery systems have led to many centers performing nearly all TF procedures percutaneously. We hypothesized that the heterogeneity and temporal variation in access strategy within PARTNER-I could provide outcome information relevant to today's TF-TAVR patient with peripheral vasculopathy.
Therefore, using all as-treated PARTNER-I trial TAVR patients, including continuing access patients, we sought to identify differences in preprocedural characteristics of patients undergoing TA-versus TF-TAVR to formulate a propensity score to account for confounding caused by these differences and then to compare outcomes.
Methods

Patients and TAVR Approaches
From April 2007 to February 2012, 2621 high-risk or inoperable patients with severe AS were enrolled in PARTNER-I and underwent TA-TAVR (n=1100) or TF-TAVR (n=1521) with large 22F and 24F TF delivery systems. TA-TAVR was performed in 19 patients as roll-in for the randomized trial, 104 in randomized PARTNER A, and 977 during nonrandomized continuing access. TF-TAVR was performed in 43 patients as roll-in, 240 in randomized PARTNER A, 175 in randomized PARTNER B, 40 during randomized continuing access for inoperable patients, and 1023 during nonrandomized continuing access for high-risk patients (Table I in the online-only Data Supplement) .
This as-treated PARTNER-I study is based on data that the sponsor, Edwards Lifesciences, provided to the PARTNER Publications Office in February 2013 for independent unrestricted analysis and publication. The Institutional Review Board at each participating institution approved the study, and all patients provided written informed consent.
End Points
Time 0 for this study was date of TAVR. End points were (1) in-hospital mortality, stroke, other periprocedural morbidities, postprocedural length of hospital stay, postprocedural aortic regurgitation (AR), and New York Heart Association functional class; (2) time-related all-cause stroke (including in-hospital stroke); and (3) time-related all-cause mortality (including in-hospital mortality). An independent Clinical Events Committee adjudicated all events.
Postprocedural AR-paravalvular, transvalvular, and total-was the integration of central and paraprosthetic and was graded as none/ trace, mild, moderate, or severe. 7 Stroke definitions were similar to those subsequently incorporated into the Valve Academic Research Consortium definitions. 8 
Data Analysis
Analyses were performed with SAS statistical software (SAS version 9.2; SAS, Inc, Cary, NC) and R software version 2.15.3. 
Differences in Patient Characteristics
Baseline characteristics of TF-TAVR and TA-TAVR patients differed ( Figure 1 and Table II in the online-only Data Supplement), most notably with respect to the presence of vasculopathy. Statistically significant differences between groups were identified by logistic Figure 1 . Covariable balance for selected variables before (triangles) and after (squares) matching, contrasting characteristics of patients undergoing transapical (TA) transcatheter aortic valve replacement (TAVR) and transfemoral (TF) TAVR. Values on the horizontal axis represent percent standardized difference. Peripheral arterial disease has been suppressed in this graph; it had a standardized value of 130, the strongest correlate of a TA-TAVR procedure. Triangles to the left of zero (negative) represent TF-TAVR-like characteristics; those to the right, TA-TAVR-like characteristics. The magnitude of standardized difference relates directly to the magnitude of the relative difference between the 2 groups. Squares represent standardized difference after propensity matching. All are well within 10%. CABG indicates coronary artery bypass grafting; CEA, carotid endarterectomy; LV, left ventricular; and PCI, percutaneous coronary intervention.
by guest on May 1, 2017 http://circ.ahajournals.org/ Downloaded from regression (PROC LOGISTIC) using only preprocedural variables (Appendix I in the online-only Data Supplement), including a diagnosis of peripheral arterial disease (PAD; defined for the PARTNER-I trial as narrowing or blockage of arteries in the limbs or distal aorta, often previously treated). However, certain details of iliofemoral disease were not considered because they either were explicit criteria for TA-TAVR during the randomized portion of the trial or may have led to an inability to perform TF-TAVR.
To meet assumptions of linearity of ordinal and continuous variables with respect to the logit, we selected transformations of scale that would ensure linearity. Thereafter, variable selection, with a P value criterion for retention of variables in the model of 0.05, used bagging (bootstrap aggregation) 10, 11 with automated forward stepwise analysis of 500 resampled data sets. Variables appearing in at least 50% of analyses were considered reliably statistically significant. The primary differences between groups were related to PAD, other vasculopathies, hypertension, and more recent date of implantation in the TA-TAVR group and to porcelain aorta in the TF-TAVR group (Table 1 and Figure II in the online-only Data Supplement).
Accounting for Confounding in Assessing Outcomes
To address confounding caused by these differing baseline patient characteristics, we adopted propensity score-based matching. 12, 13 Inclusion and exclusion criteria were data driven by estimating the propensity of a given patient to undergo TF-or TA-TAVR, no matter what access strategy was actually used. On one extreme were patients with a strong propensity for TA-TAVR, and at the other were patients with a strong propensity for TF-TAVR (Figure 2) . In between were patients who had similar characteristics between groups-a zone of virtual equipoise-and these were the patients considered in the comparison of outcomes.
Developing the propensity score began with the parsimonious model described previously, to which we added other preprocedural variables, no matter their statistical significance, that might be related to unrecorded selection factors. In all, 111 variables were incorporated into a semisaturated propensity model (Appendix I in the online-only Data Supplement). In this analysis, we suppressed from consideration perceived or actual contraindications to TF-TAVR to make outcomes comparisons in the absence of physical impediments to performing TF-TAVR. 
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Using the resulting logistic equation, we calculated the probability of each patient being in the TA-TAVR group: the propensity score. Using only the propensity score, we matched TA-TAVR cases one-to-one to TF-TAVR cases using a greedy matching strategy. 14 TA-TAVR cases with propensity scores that deviated >0.10 from those of TF-TAVR cases were considered unmatched. 15 A total of 501 patient pairs were matched, 46% of the potential matches. Although TA-TAVR and TF-TAVR patients were matched across the entire spectrum of propensity scores, 1020 TF-TAVR patients were unmatched because of a nearly zero probability of being in the TA-TAVR group, and 599 TA-TAVR patients were unmatched because of a nearly 100% probability of being in the TA-TAVR group (see Figure 2) . Matched patients were well matched with respect to the 111 variables included in the propensity model (Table 2 and Figure 1 ). Of note, 95% of patients in both matched groups had PAD.
Because we were able to match fewer than half the potential patient pairs, we performed 2 further analyses. First, we developed a propensity score without accounting for PAD. This resulted in 731 matched patient pairs, 66% of the potential matches. Results of comparisons of all outcomes were consistent with those from the primary analysis and are not reported. Second, we performed an in-depth analysis of outcomes in unmatched TA-TAVR and TF-TAVR patients from the primary analysis. (Baseline characteristics for these patients are listed in Table III This table demonstrates the similarity of groups based on matching on propensity score alone. ACE indicates angiotensin-converting enzyme; BMI, body mass index; CABG, coronary artery bypass grafting; LAD, left anterior descending; LITA, left internal thoracic artery; LMT, left main trunk; NYHA, New York Heart Association; PAD, peripheral arterial disease; PCI, percutaneous coronary intervention; RITA, right internal thoracic artery; TA-TAVR, transapical transcatheter aortic valve replacement; and TF-TAVR, transfemoral transcatheter aortic valve replacement.
*Patients with data available. †The 15th/50th/85th percentiles. 
Time-Related Events Analysis
For matched TA-TAVR patients, the median follow-up was 1 year (mean±SD, 1.3±0.92 years); 638 patient-years of data were available for analyses. Twenty-five percent of the survivors were followed up for >2 years, and 10% were followed up for >3 years. For matched TF-TAVR patients, the median follow-up was 1 year (mean±SD, 1.3±0.87 years); 662 patient-years of data were available for analyses. Twenty-five percent of the survivors were followed up for >2 years and 10% were followed up for >3 years. Time-related mortality and stroke were estimated nonparametrically by the Kaplan-Meier method and parametrically by a multiphase non-proportional hazards model, 16 by which a smooth representation of instantaneous risk (hazard function) of these events was estimated across time.
Longitudinal Data Analysis
New York Heart Association functional class and ordinal measurements of AR grade were recorded for each patient at discharge and 30 days and 6 months after TAVR. To analyze these ordinal longitudinal (repeated measures) data, a marginal cumulative logistic regression (PROC GENMOD SAS) was used with a generalized estimating equation method of parameter estimation for correlated data.
Managing Missing Values
Appendix II in the online-only Data Supplement describes our multiple imputation strategy. Briefly, to account for missing values for some variables in multivariable modeling, we performed 5-fold multiple imputation using a Markov chain Monte Carlo technique 17 to yield final regression coefficient estimates, the variance-covariance matrix, and P values.
Presentation
Continuous data are presented as mean±SD or equivalent 15th, 50th (median), and 85th percentiles when the distribution is skewed. Odds ratios and time-related estimates are presented with 95% confidence intervals.
Comparisons of continuous variables were made with Wilcoxon rank-sum nonparametric tests. Categorical data are summarized by frequencies and percentages; comparisons were made with χ 2 tests or the Fisher exact test when the frequency was <5. Comparisons of periprocedural outcomes in the propensity-matched cohort were made with paired tests: the McNemar test for binary variables and paired t tests for continuous variables. Because transformation of scale of continuous variables was often necessary to meet statistical model assumptions, results of logistic regression modeling are presented with their coefficients, as well as odds ratios for binary variables and nomograms for continuous variables.
Results
Periprocedural Outcomes
Procedure time was similar for propensity-matched TA-and TF-TAVR patients (median, 106 versus 104 minutes; P=0.9; Table 3 ). However, among TA-TAVR patients, the median fluoroscopy time was shorter (12 versus 22 minutes; P<0.0001) and contrast volume was less (90 versus 120 mL; P<0.0001). A greater number of 26-mm prostheses were inserted in matched TA-TAVR patients than in matched TF-TAVR patients (53% versus 45%; P=0.016), although median cover index, the ratio of the difference between prosthesis size and anulus diameter in systole to prosthesis size, 18 was similar. In-hospital mortality was higher after TA-TAVR than TF-TAVR in matched patients (n=37 [7.4%] Figure 3 ; adverse events among all patients are presented in Table  IV Propensity-matched TA-TAVR patients were more likely than TF-TAVR patients to have none/trace postprocedural AR (57% versus 35%; P=0.001), although the majority (91% and 87%) had mild or less AR at hospital discharge. This difference persisted at 30 days (none/trace AR, 50% versus 39%; P=0.001) and 6 months (none/trace AR, 54% versus 35%; P<0.0001; Figure 4 ). In the 23-mm valve subgroup, TF-TAVR patients had more paravalvular AR than TA-TAVR patients at discharge, 30 days, and 6 months. In the 26-mm subgroup, TF-TAVR patients had more paravalvular AR at discharge but similar paravalvular AR at 30 days and 6 months (Table V in the online-only Data Supplement).
Recovery after TA-TAVR, as assessed by New York Heart Association class, was slower than after TF-TAVR (New York Heart Association class: overall P=0.17 at discharge and P=0.0003 at 30 days; Figure 5 ). However, New York Heart Association class was similar by 6 months (P=0.5).
Stroke
A total of 47 propensity-matched patients experienced a stroke during initial hospitalization and follow-up, 23 in the TA-TAVR group and 24 in the TF-TAVR group. The probability of stroke at 30 days, 6 months, and 1, 2, and 3 years was 3.4% versus 3.3%, 4.0% versus 3.8%, 4.5% versus 4.4%, 5.3% versus 5.5%, and 6.0% versus 6.7% for TA-TAVR and TF-TAVR patients, respectively ( Figure 6 ). Instantaneous risk for stroke demonstrated an early peaking hazard ( Figure  III in the online-only Data Supplement). Although the contour of risk was somewhat different in the first few days after TA-and TF-TAVR, this difference was not statistically significant (P>0.9), and the hazard levels to which each cohort fell also were not significantly different (P=0.9). The probability of stroke after accounting for death as a competing risk in the propensity-matched cohort also shows no difference between the groups (Figure IV in the online-only Data Supplement).
Mortality
A total of 304 propensity-matched patients died either in hospital or during follow-up, 167 in the TA-TAVR group and 137 in the TF-TAVR group. The probability of death after TA-TAVR versus TF-TAVR at 30 days, 6 months, and 1, 2, and 3 years was 9.1% versus 3.7%, 19% versus 12%, 26% versus 19%, 37% versus 33%, and 47% versus 45%, respectively ( Figure 7A ). This resulted from an instantaneous risk for death that demonstrated an early rapidly decreasing phase and an intermediate-term nearly constant hazard phase ( Figure 7B ). There was a higher early risk of death after TA-TAVR compared with TF-TAVR among matched patients (P=0.01), but after ≈4 months, the 2 hazard functions converged such that risk of death was similar in the intermediate term (P=0.5). This is reflected in the early separation of mortality curves from higher periprocedural deaths after TA-TAVR than after TF-TAVR ( Figure 7B, inset) . Both overall and among matched patients, modes of death were generally equally distributed between cardiovascular and noncardiovascular (Table 4 and Table VI in the onlineonly Data Supplement), although uncategorizable deaths were numerous. Early risk of cardiovascular death was higher after TA-TAVR than TF-TAVR (P=0.04), but risk of late cardiovascular death was similar (P=0.13) although numerically higher for TF-TAVR than TA-TAVR (Figure VA in the online-only Data Supplement), resulting in the probability of cardiovascular death converging for these groups (Figure VB in the online-only Data Supplement) by ≈30 months. Risk of noncardiovascular death early after TA-TAVR was also higher (P=0.02), but risk of late noncardiovascular death was similar (P=0.6; Figure VC and VD in the online-only Data Supplement).
Outcomes Among Unmatched Patients
Characteristics of unmatched TA-TAVR patients differed to some extent from those of matched TA-TAVR patients (compare Table 2 with Table III in the online-only Data Supplement), but their early outcomes and mortality were generally similar (compare Table 3 with Table VII in (compare Table 2 with Table III in the online-only Data Supplement). The result was that early outcomes and mortality among unmatched TF-TAVR patients were worse than those among matched TF-TAVR patients (compare Table 3 with Table VII in 
Discussion Principal Findings
This study demonstrates that, in matched patients with similar degrees of PAD and extensive cardiovascular risk factors, TA-TAVR is associated with greater periprocedural morbidity and mortality than TF-TAVR. This was true overall ( Figure VIII in the online-only Data Supplement) and in propensity-matched comparisons. TA-TAVR was associated with longer postprocedural hospital stay and slower recovery, but less postprocedural AR than TF-TAVR. The higher stroke risk after TA-TAVR observed in the randomized trial was progressively neutralized during continuing access ( Figure IX in the online-only Data Supplement), and any remaining differences in periprocedural or late stroke risk are attributable to chance alone and may be trending lower.
Finally, we have identified a group of patients with PAD and other cardiovascular risk factors who are well matched for either TA-or TF-TAVR. If it is possible to perform TF-TAVR in these patients or if TF-TAVR becomes possible with smaller delivery systems, these patients should experience fewer adverse events and faster recovery despite incurring more paravalvular AR.
Results in Context
Differences in Patient Characteristics
There were fundamental baseline differences between TAand TF-TAVR patient characteristics, the most conspicuous being PAD with limited ability to use TF access owing to iliofemoral morphology and pathology and the size of sheath used during the PARTNER-I trial. Patients undergoing TA-TAVR had more cardiovascular risk factors accompanying their advanced iliofemoral disease, including hypertension, hyperlipidemia, coronary artery disease, and cerebrovascular disease. In contrast, TF-TAVR patients had more severe AS, more extensive left ventricular remodeling, and more frequent noncardiovascular morbidities (Figure 1 ).
Despite these different patient characteristics, we discovered similarities between these groups and were able to match patients using a propensity score. Thus, for the first time, comparisons can be made between patients who are typical for TA-TAVR but not for TF-TAVR. Although it is currently unknown whether similar trends will persist in lower-risk populations or after further accrual of experience, these data reflect contemporary outcomes of closely controlled TA-and TF-TAVR high-risk patient subsets and suggest that further efforts to diminish early outcome differences between access groups are warranted. These data also validate the utility of smaller TAVR devices available today that permit TAVR patients with PAD to undergo a TF procedure.
Differences in Outcome
Differences in paravalvular AR may have affected survival in the 2 groups, especially considering that they were not matched on this postprocedural outcome, which has been shown to contribute to late mortality. 19, 20 TA-TAVR patients had less paravalvular AR, potentially because TA access to the aortic valve is more direct, which facilitates more accurate positioning and deployment of the prosthesis and allows insertion of a larger prosthesis. Alternatively, because more AR was associated with 23-mm prostheses in TF-TAVR patients, operators may have downsized the valve to facilitate TF access. This is an important advantage of TA-over TF-TAVR in the context of using older second-generation transcatheter heart valves. Transfemoral access was sometimes limited because of iliofemoral artery size and stenotic disease. Transfemoral delivery systems have subsequently become lower profile, thus facilitating implantation of larger devices capable of improving anular coverage and diminishing the likelihood of paravalvular AR. Furthermore, TA-TAVR was not available early in the trial, and some patients may have received an undersized valve via TF-TAVR.
To understand the stroke findings, we have examined time-related stroke data in unadjusted groups and in matched versus unmatched patients. The risk of stroke was similar in randomized and nonrandomized continuing access TF-TAVR patients. In the randomized TA-TAVR study group, however, early risk of stoke was substantially higher than in the nonrandomized continuing access patients, as first reported by Dewey and colleagues. 21 Other reports confirm a survival advantage after TF-TAVR compared with alternative access approaches. The UK transcatheter aortic valve insertion registry reported outcomes of 1620 patients undergoing TAVR. Mortality after TA-TAVR versus TF-TAVR was found to be higher at 30 days (11.2% versus 4.4%; P<0.01), 1 year (28.7% versus 18.1%; P=0.01), and 2 years (56% versus 43.5%; P=0.01). 22 After adjustment for influential prognostic risk factors, TA-TAVR was still associated with increased mortality. The French Transcatheter Aortic Valve Intervention Registry (FRANCE 2 Registry) demonstrated similarly increased mortality after TA-versus TF-TAVR, both unadjusted and risk adjusted. 23 A recent report from another European registry demonstrated that early hazard of death was higher after TA-TAVR than TF-TAVR, but the long-term prognosis was equivalent. 24 As experience with patient selection and performing TA-TAVR grew, early mortality and complications diminished. 21 Whether further improvement is achievable with other anatomic approaches such as direct transaortic is unknown.
If TA-TAVR is associated with increased early mortality, are patient or procedure factors more influential? Patients were rigorously matched in this study, and in the absence of a trial with randomized assignment of anatomic access, these results, along with those of large registry experiences, are important in formulating perspectives on this issue. This analysis suggests that the surgical procedure is more influential.
Future results obtained with subsequent iterations of TAVR devices will put these early results, which reflect the outcomes of large second-generation TAVR devices used in high-risk patients, into proper context. With smaller valve and deployment systems, greater technical facility, and refined patient selection, outcomes are anticipated to improve. Whether the mortality superiority of the TF-TAVR approach identified in the present report will persist in third-and fourth-generation device trials and lower-risk patient cohorts is unknown. Finally, if the mortality penalty associated with TA-TAVR is attributed to ventricular myocardial damage from ventriculotomy and repair, lower-profile devices, along with less invasive port-like delivery and control systems, might alter future TA-TAVR outcomes. At present, however, our results and large registry experiences detailing results of second-generation TF-TAVR procedures appear to favor TF-first access when anatomically feasible.
Limitations
The comparison of TA-and TF-TAVR outcomes is fraught with potential problems barring a randomized trial, which would be feasible only for patients in whom TF access was possible. A TF-first strategy was used in the randomized phase of the PARTNER-I trial; therefore, TA-TAVR was considered the bailout option, not only for lack of access as a result of PAD but also for occasional intraprocedural failure to cross the iliofemoral vascular system, necessitating crossover to TA-TAVR.
Propensity matching resulted in a comparison between TAand TF-TAVR patients with PAD and cardiovascular risk factors. Hence, the definition of PAD is paramount. The greater prevalence of coronary artery disease, percutaneous coronary intervention, coronary artery bypass grafting, carotid disease, carotid endarterectomy, hyperlipidemia, hypertension, and β-blocker use in the TA-TAVR group became balanced in the matched TF-TAVR group, and the prevalence of these diseases mirrors that of the TA-TAVR group before matching.
The older second-generation valves and large delivery systems used in PARTNER-I have been replaced by smaller delivery systems and improved valves.
Caution must be exercised in interpreting our results as indicating cause and effect. Although 111 variables were used for propensity matching, other factors importantly related to access decisions such as quantitative assessment of frailty or latent processes of the event may not have been recorded or measured. Outcomes comparisons do not take into account that some outcomes may be causally linked.
A general limitation of propensity score methodology is that it does not address risk factors for outcomes but compares average outcomes in matched patients much like randomized trials. The reason is that it attempts to reconstruct the patient allocation rule and to examine outcomes of matched patients, rather than starting with outcomes and identifying risk factors, including access. 13 Comprehensive multivariable analyses of outcomes such as death and stroke are underway and will identify their risk factors.
Conclusions
In well-matched high-risk or inoperable AS patients, nearly all of whom had PAD, despite less AR and comparable risk of stroke, adverse periprocedural events, early mortality, and prolonged recovery were greater after TA-TAVR than TF-TAVR. Mechanisms for this increased early risk require further study to identify possible ways to ameliorate it. Whether direct transaortic or subclavian TAVR can be performed with lower risk awaits either a randomized trial or a propensity scorebased approach similar to that used in this study. At the present time, we recommend a TF-first access strategy for TAVR when anatomically feasible.
Sources of Funding
The PARTNER Trial was funded by Edwards Lifesciences; the protocol was developed collaboratively by the sponsor and the Steering Committee. 
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CLINICAL PERSPECTIVE
Severe senile calcific aortic valve stenosis is often associated with multiple age-related comorbidities that increase risks after conventional surgical aortic valve replacement. Transcatheter aortic valve replacement (TAVR) is a therapeutic alternative for these high-risk or inoperable patients. Patients in the Placement of Aortic Transcatheter Valves (PARTNER)-I trial underwent TAVR via transfemoral (TF) or transapical (TA) access with a second-generation bovine pericardial transcatheter valve. During the randomized phase of the trial, a TF-first allocation strategy was used, reserving TA access for patients with impediments to navigation of the iliofemoral arteries; however, during nonrandomized continuing access, an increasing proportion of valves were inserted via TA access as more vasculopathic patients underwent TAVR. As transcatheter device technology advances, we anticipate that many such patients will be amenable to TF-TAVR. Thus, we propensity matched TA-TAVR and TF-TAVR patients using 111 variables, thereby permitting comparison of outcomes of 2 well-matched cohorts of patients, 95% of whom had peripheral arterial disease. Compared with TF-TAVR, we found that TA-TAVR was associated with greater periprocedural morbidity and mortality, longer postprocedural hospital stay, and slower recovery but less prosthesis-related aortic regurgitation. The higher stroke risk after TA-TAVR observed in the randomized trial was progressively neutralized during continuing access. Thus, at the present time, we recommend a TF-first access strategy for TAVR when anatomically feasible. As smaller delivery systems become available, patients should experience fewer adverse events and faster recovery after TF-TAVR despite incurring more paravalvular aortic regurgitation, which itself may be mitigated by advances in percutaneous valve technology. 
Functional Health Status
Syncope not related to complete atrioventricular heart block*, exertional syncope*, heart failure*, New York Heart Association functional class*
Aortic Valve Pathophysiology (Including Echocardiographic Studies)
Prior balloon aortic valvotomy*, aortic valve calcification with bulky cusp nodules, native valve calcified*, calcified anulus*, dilated anulus, native valve cusp fusion*, aortic valve area, aortic valve peak velocity (cm/sec)*, time-velocity integral (cm)*, effective orifice area (cm 
Ventricular Function
Prior myocardial infarction*
Other Cardiac Comorbidity
Mitral valve disease*, baseline mitral valve regurgitation severity*, tricuspid valve disease*, history of endocarditis, atrial fibrillation*, atrial flutter, major arrhythmia*, pacemaker implant*, cardiomyopathy*, rheumatic fever, hypertension*, prior cardiac surgery*, other prior cardiovascular interventions*
Pre-Balloon Aortic Valvotomy Catheterization Hemodynamics (mmHg)
Pulmonary artery (PA) diastolic pressure*, PA systolic pressure*, mean PA pressure, aortic diastolic pressure*, aortic systolic pressure*, mean aortic pressure*, mean aortic valve gradient*, mean right atrial pressure*
Noncardiac Comorbidity
Chest wall deformity*, chest wall radiation changes*, diabetes (yes/no, Types I and II, mild-to-moderate, with end organ damage*, insulin*), smoking*, pulmonary disease*, oxygen-dependent pulmonary disease*, chronic pulmonary disease*, oxygen-dependent chronic pulmonary disease*, drug treatment (bronchodilator*, steroid*, immunosuppressant*), hyperlipidemia*, renal disease requiring hemodialysis*, renal disease requiring current hemodialysis, hepatic disease*, cirrhosis, gastrointestinal condition*, cancer*, alcohol abuse*, drug abuse, coagulopathy*, bilirubin (mg/dL)*, creatinine (mg/dL), creatinine clearance (Cockcroft-Gault, mL/min)*, glomerular filtration rate (mL/min/1.73 m 2 ), blood urea nitrogen (mg/dL)*, hemoglobin (g/dL)*, hematocrit (%)*, International Normalized Ratio*, platelet count (k/uL)*, white blood cell count (k/uL)*, albumin (g/dL)*, B-type natriuretic peptide (pg/mL)
Medication
Angiotensin-converting enzyme inhibitor*, antiarrhythmics*, anticoagulants*, antiplatelets*, beta blocker*, blood pressure*, calcium channel blocker*, diuretic*, nitrate*, statin*
Online Appendix 2. Missing Values
Of the 111 variables in this observational study, 83% had missing values ranging from 0.3% to 16%. Most variables had less than 4% missing, and a few continuous variables in the cardiac/non-cardiac comorbidity category had up to 16% missing (Online Table 2 ). In order to accommodate covariates with missing data in the parsimonious and propensity logistic-regression models, we employed five-fold multiple imputation stratified by TA-and (Table 1) .
To obtain the propensity score, we first estimated the score for each patient from the propensity model using each of the five imputed complete datasets. We then took the average of five propensity scores for each patient across the five completed datasets 2 and performed propensity score matching using the averaged propensity score. Finally, comparisons of outcomes of interest were made using the matched cohorts.
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